ARCHETYPE Revised International Staging System for Multiple Myeloma (R-ISS) (openEHR-EHR-OBSERVATION.iss-revised.v0)

ARCHETYPE IDopenEHR-EHR-OBSERVATION.iss-revised.v0
ConceptRevised International Staging System for Multiple Myeloma (R-ISS)
DescriptionA staging system for classifying and stratifying patients with multiple myeloma.
UseUse to record the results for each component parameter and the resulting R-ISS stage.
PurposeTo record the results for each component parameter and the resulting R-ISS stage.
ReferencesDurie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. PMID: 1182674.

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve]. PMID: 15809451.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. PMID: 26240224; PMCID: PMC4846284.
Copyright© Cambio CDS, openEHR Foundation
AuthorsAuthor name: Maryam Razavi
Organisation: Cambio CDS
Email: maryam.razavi@cambio.se
Date originally authored: 2020-12-22
Other Details LanguageAuthor name: Maryam Razavi
Organisation: Cambio CDS
Email: maryam.razavi@cambio.se
Date originally authored: 2020-12-22
Other Details (Language Independent)
  • Licence: This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/.
  • Custodian Organisation: openEHR Foundation
  • References: Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. PMID: 1182674. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281. Harousseau, Jean-Luc [corrected to Avet-Loiseau, Herve]. PMID: 15809451. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. PMID: 26240224; PMCID: PMC4846284.
  • Current Contact: maryam.razavi@cambio.se
  • Original Namespace: org.openehr
  • Original Publisher: openEHR Foundation
  • Custodian Namespace: org.openehr
  • MD5-CAM-1.0.1: D3CA7BEB1993FE4B9875ED5F320A7A8B
  • Build Uid: 4b7a5d0a-e304-40d5-a440-19f406e1af59
  • Revision: 0.0.1-alpha
Keywordsalbumin, multiple, myeloma, staging, system
Lifecyclein_development
UID0e6143ea-715b-4d6a-a5b7-f23b91ccf8cd
Language useden
Citeable Identifier1246.145.2861
Revision Number0.0.1-alpha
protocol
ExtensionExtension: Additional information required to extend the model with local content or to align with other reference models or formalisms.
For example: local information requirements; or additional metadata to align with FHIR.
Include:
All not explicitly excluded archetypes
data
Serum β2 microglobulinSerum β2 microglobulin:
  • <3.5 mg/L
  • 3.5-5.4 mg/L
  • >5.4 mg/L
Serum albuminSerum albumin:
  • <3.5 g/dL
  • ≥3.5 g/dL
ISS stageISS stage:
  • ISS I [Serum β2-microglobulin <3.5 mg/L and serum albumin ≥3.5 g/dL.]
  • ISS II [Not stage I or III.]
  • ISS III [Serum β2-microglobulin ≥5.5 mg/L.]
CA by iFISHCA by iFISH: Chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH).
  • Standard risk [No high risk CA.]
  • High risk [Presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16).]
Serum LDHSerum LDH:
  • Normal [Serum LDH < the upper limit of normal.]
  • High [Serum LDH > the upper limit of normal.]
Revised ISS stageRevised ISS stage:
  • R-ISS I [ISS stage I and standard-risk CA by iFISH and normal LDH.]
  • R-ISS II [Not R-ISS stage I or III.]
  • R-ISS III [ISS stage III and either high-risk CA by iFISH or high LDH.]
events
Any eventAny event: Default, unspecified point in time or interval event which may be explicitly defined in a template or at run-time.
Other contributorsSilje Ljosland Bakke, Helse Vest IKT AS, Norway (openEHR Editor)
Heather Leslie, Atomica Informatics, Australia (openEHR Editor)
Translators